Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

NCT02955589 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult T-Cell Lymphoma (ATL)

Interventions

DRUG: HBI-8000

Sponsor

HUYABIO International, LLC.

Collaborators

[object Object]